Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28571619 | 0.86 | CYP1A2 (0.49) | SMN1; SMN2ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL514164 | 0.86 | CYP1A2 (0.49) | SMN1; SMN2ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL2634575 | 0.83 | PTGS2 (0.46) | MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL994450 | 0.80 | MAPT (0.46) | MAPTRAB9AL3MBTL1CASP3SENP8 | |
| SCHEMBL994448 | 0.80 | MAPT (0.46) | MAPTRAB9AL3MBTL1CASP3SENP8 | |
| SCHEMBL28603686 | 0.78 | ALOX5 (0.46) | MAPTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL28556997 | 0.76 | CYP1A2 (0.46) | MAPTRAB9AL3MBTL1CASP3SENP8 | |
| SCHEMBL21835014 | 0.76 | MAPT (0.38) | MAPTRAB9AL3MBTL1CASP3SENP8 | |
| SCHEMBL113258 | 0.75 | PPARA (0.44) | MAPTRAB9AL3MBTL1CASP3SENP8 | |
| SCHEMBL28243883 | 0.75 | PPARA (0.44) | MAPTRAB9AL3MBTL1CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023096904-A2 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4164752-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| EP-4081527-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021252708-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021133601-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3307728-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | Dana Farber Cancer Institute, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017190038-A1 | ANALOGS OF YOHIMBINE AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016154317-A2 | POLYMERS, HYDROGELS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016115463-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016081732-A1 | THIENOPYRIMIDINES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-05-26 | — | — | WO | disclosed |
| EP-2438046-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141074-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-09 | — | — | WO | disclosed |